Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ISAL 2023 | ENHANCE-2 and ENHANCE-3: exploring magrolimab combinations in AML

David Sallman • 20 Mar 2023
ISAL 2023
Acute Myeloid Leukemia Leukemia Antibodies Azacitidine Magrolimab Venetoclax
ENHANCE-2 ENHANCE-3

David Sallman, MD, Moffitt Cancer Center, Tampa, FL, gives an overview of the ENHANCE-2 and ENHANCE-3 trials (NCT04778397; NCT05079230), which are evaluating doublet and triplet combinations with magrolimab in patients with acute myeloid leukemia (AML). This interview took place at the 18th International Symposium on Acute Leukemias (ISAL XVIII), held in Munich, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from David Sallman

2:08
Hematological response to frontline treatment in LR-MDS is associated with better OS
David Sallman • 9 Dec 2023
1:58
Canakinumab plus darbepoetin in patients with LR-MDS following ESA failure
David Sallman • 9 Dec 2023
2:49
Front-line treatment options for HR-MDS: can we move past azacitidine?
David Sallman • 9 Dec 2023
Transplantation & immunotherapies
Charles Craddock et al. • 4 Sep 2023

Related Videos

2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
1:48
Do all patients require maintenance therapy following alloSCT?
Mark Levis • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals